The energetic burden of continuously concentrating solutes against gradients along the tubule may render the kidney especially vulnerable to ischaemia. Acute kidney injury (AKI) affects 3% of all hospitalized patients 1,2 . Here we show that the mitochondrial biogenesis regulator, PGC1α 3,4 , is a pivotal determinant of renal recovery from injury by regulating nicotinamide adenine dinucleotide (NAD) biosynthesis. Following renal ischaemia, Pgc1α −/− (also known as Ppargc1a −/− ) mice develop local deficiency of the NAD precursor niacinamide (NAM, also known as nicotinamide), marked fat accumulation, and failure to reestablish normal function. Notably, exogenous NAM improves local NAD levels, fat accumulation, and renal function in post-ischaemic Pgc1α −/− mice. Inducible tubular transgenic mice (iNephPGC1α) recapitulate the effects of NAM supplementation, including more local NAD and less fat accumulation with better renal function after ischaemia. PGC1α coordinately upregulates the enzymes that synthesize NAD de novo from amino acids whereas PGC1α deficiency or AKI attenuates the de novo pathway. NAM enhances NAD via the enzyme NAMPT and augments production of the fat breakdown product β-hydroxybutyrate, leading to increased production of prostaglandin PGE 2 (ref. 5), a secreted autacoid that maintains renal function. NAM treatment reverses established ischaemic AKI and also prevented AKI in an unrelated toxic model. Inhibition of β-hydroxybutyrate signalling or prostaglandin production similarly abolishes PGC1α-dependent renoprotection. Given the importance of mitochondrial health in ageing and the function of metabolically active organs, the results implicate NAM and NAD as key effectors for achieving PGC1α-dependent stress resistance.
. We hypothesized that PGC1α (peroxisome proliferator activated receptor gamma co-activator-1-α), enriched in renal tubules and important for stress resistance in the brain, heart and other metabolically active organs 4, [7] [8] [9] [10] [11] , regulates oxidative metabolism in the epithelium to affect overall kidney health.
Hans Krebs identified acylglycerols as a major renal fuel 12 . Following transient local ischaemia, renal function worsened, PGC1α expression declined, tubular mitochondria swelled, and a pronounced accumulation of acylglycerols developed in tubules (P < 0.0001, Fig. 1a -e, Extended Data Fig. 1a-c) . The fidelity of serum creatinine was confirmed by comparison to cystatin C and inulin clearance (Extended Data Fig. 1d-f ). Pgc1α −/− mice experienced worse renal function, greater fat accumulation, and more tubular injury following ischaemia (Fig. 1f, Extended Data Fig. 2a-g ). To define pathways specific to PGC1α altered by ischaemia, we examined metabolite profiles. Comparing sham with post-ischaemic kidneys yielded six differentially abundant metabolites; comparing uninjured Pgc1α −/− to wildtype littermate kidneys yielded 11. Four were shared between settings, Signi cance level (-log 10 
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Figure 1 | NAM supplementation restores normal post-ischaemic response in Pgc1α
−/− mice. a, b, Pre-ischaemic normal morphology (a) and swollen mitochondria (b) inside tubular cells 24 h after ischaemiareperfusion injury (IRI). Scale bars, 200 nm. c, Renal di-/tri-acylglycerols (DAGs, TAGs) 24 h following sham or IRI (n = 6 per group). P value determined by ANOVA. d, e, Oil-Red-O staining (pink) for fat in normal and post-ischaemic kidneys. Scale bars, 20 μm. f, Serum creatinine in wild-type (WT) versus Pgc1α −/− (KO) mice (basal, n = 7 per group; postischaemia, n = 18 per group). g, h, Volcano plots of kidney metabolites from knockout versus wild type or IRI versus sham (univariate P < 0.05 for coloured dots, n = 6 per group). i, Serum creatinine in post-ischaemic wild-type versus knockout mice treated with vehicle (Veh., n = 5) versus NAM (n = 9). Error bars, s.e.m.; *P < 0.05, **P < 0.01.
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−/− and post-ischaemic kidneys (Fig. 1g , h, Extended Data Fig. 3a, b ).
Of these, carnitine deficiency in Pgc1α −/− and post-ischaemic kidneys supported mitochondrial involvement in both situations. Deficiency of betaine and choline, two osmolytes essential for cell volume maintenance in the uniquely hypertonic renal environment, was not unanticipated. We therefore focused on NAM, the predominant mammalian precursor to synthesize the energy carrier NAD needed for fatty acid oxidation (FAO) 13 . After confirming the metabolomics results (Extended Data Fig. 3c -e), we tested the effect of NAM supplementation. Exogenous NAM increased renal NAM (P < 0.001), normalized post-ischaemic fat accumulation, and completely prevented post-ischaemic AKI in Pgc1α −/− mice (Fig. 1i , Extended Data Fig. 3f-h ), implicating this metabolite as an unexpected effector of PGC1α.
To probe the robustness of PGC1α's relation to NAM, fat accumulation, and renal function, we developed an inducible tubular epithelial transgenic model using the well-validated Pax8 promoter (iNephPGC1α) 14 . Heterologous PGC1α was tightly controlled without leaky gene expression; organ size and mass were indistinguishable; and mitochondrial abundance increased-as assessed by comparing mitochondrial to nuclear DNA and mitochondrial gene products to cytosolic gene products-without altering ultrastructural morphology or the anatomical distribution favouring cortex and outer stripe of the outer medulla (Fig. 2a-c , Extended Data Fig. 4a-i ). iNephPGC1α mice tolerated renal ischaemia more successfully, achieving better survival (P = 0.0039), more preserved function (P < 0.0001), better kidney perfusion, and less tubular injury ( Fig. 2d-k, Extended Data Fig. 4j, k) . Sham-operated mice experienced no significant change in creatinine or reduced survival. Renal NAM was higher in post-ischaemic iNephPGC1α mice, and postischaemic fat accumulation was markedly reduced compared to controls (P < 0.01, Fig. 2l-q) . Renal protection in iNephPGC1α mice was shared across distinct models as post-inflammatory renal injury was also attenuated (Extended Data Fig. 5a ). PGC1α's effect appeared to be cell-type specific as endothelial overexpression conferred no renoprotection (Extended Data Fig. 5b ).
RNA sequencing identified 1,160 transcripts associated with PGC1α-dependent renoprotection (Fig. 3a, Supplementary Information Table 1 ). The pathways most over-represented related to intermediary metabolism (Fig. 3b) . Closer examination revealed that de novo NAD biosynthetic enzymes were coordinately regulated, induced in uninjured iNephPGC1α kidneys and suppressed in post-ischaemic or uninjured Pgc1α −/− kidneys ( Fig. 3c-f ). The effect of PGC1α on the de novo pathway was cell-autonomous, as knockdown in isolated renal tubular cells was sufficient to suppress the pathway (P = 0.0001, Extended Data Fig. 6a ).
As epithelial PGC1α defended renal function and resolved postischaemic fat accumulation, we hypothesized that protection from AKI may relate to NAM, NAD, and fatty acid utilization. Indeed, exogenous in cortex and outer stripe of outer medulla (OSOM) 24 h after IRI representative of 8 animals per group. Scale bar, 100 μm. l-o, Oil-red-O staining (pink) for fat in iNephPGC1α mice and controls 24 h after IRI representative of 8 animals per group. Scale bars, 200 μm (top) and 50 μm (bottom). p, Renal di-/tri-acylglycerols (DAGs/TAGs) in post-ischaemic iNephPGC1α mice relative to controls (n = 6 per group). q, Relative renal NAM 24 h after IRI (n = 6 per group). Error bars, s.e.m.; *P < 0.05. 
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Letter reSeArCH NAM dose-dependently increased renal NAD and drove local accumulation of the fatty acid breakdown product β-hydroxybutyrate (β-OHB) to approximately tenfold higher than normal circulating concentrations (P < 0.0001, Fig. 3g and Extended Data Fig. 6b, c) . β-OHB activates HCAR2, a G-protein coupled receptor that induces the renoprotective prostaglandin PGE 2 (ref. 5) . Silencing or chemical inhibition of HCAR2 markedly reduced both basal and ligand-dependent PGE 2 secretion (Fig. 3h, Extended Data Fig. 6d, e) . NAM augmented PGE 2 secretion, requiring conversion to NAD via the enzyme NAMPT to do so (Fig. 3i , Extended Data Fig. 6f, g ) 15 . Silencing of PGC1α reduced each intermediate, lowering the cellular NAD and secreted β-OHB and PGE 2 ( Fig. 3j-l) . In PGC1α-silenced cells, excess β-OHB was still able to induce PGE 2 secretion (P < 0.0001, Extended Data Fig. 6h ). Finally, renal levels of each component mirrored the cellular results, with opposing effects of PGC1α deficiency and excess on NAD, β-OHB, and PGE 2 ( Fig. 3m-o, Extended Data Fig. 7a-c) . Together, these results implicated PGC1α-dependent NAD production as an important determinant of cellular metabolism that induces renoprotective molecules (Fig. 3p) .
To test this further, we inhibited β-OHB signalling with mepenzolate bromide or prostaglandin synthesis with indomethacin in iNephPGC1α mice subjected to ischaemia. Renal protection was similarly abolished in either setting, confirming their roles as PGC1α effectors (Fig. 4a, b , Extended Data Fig. 7d, e) . Since NAM prevented ischaemic AKI in Pgc1α −/− mice, we then asked whether NAM has a broader therapeutic role. NAM administered after established AKI significantly improved renal function (P = 0.0011, Fig. 4c ). We also observed that renal NAM declined following cisplatin, a chemotherapy that injures the kidney through a mechanism considered distinct from ischaemia (Extended Data Fig. 7f, g ). NAM supplementation prevented cisplatin-induced AKI (Fig. 4d, e) . Finally, we found that PGC1α expression in human AKI was strongly suppressed, even in histologically normal regions of renal tissue (Fig. 4f-h , Extended Data Fig. 8a-f) , mirroring the AKI-induced suppression of PGC1α observed in experimental models (Extended Data Fig. 1c  and ref. 7) . These results show that PGC1α is a negatively regulated target in AKI. h, Conditioned-media-PGE 2 of renal tubular cells after HCAR2 knockdown with and without HCAR2 stimulation (+, niacin 10 mM, n = 6 per condition). i, PGE 2 from renal cells following NAM (1 μM for 24 h) with and without NAMPT inhibitor FK866 (10 nM, n = 6 per condition). j-l, Intracellular NAD, conditioned-media β-hydroxybutyrate (β-OHB), and conditioned-media PGE 2 in PGC1α knockdown cells (n = 6 per condition). m-o, Relative renal NAD, β-OHB, and PGE 2 in control versus iNephPGC1α mice (n = 6 per group). *P < 0.05, **P < 0.01, ***P < 0.001. p, Renal epithelial PGC1α coordinately upregulates de novo NAD biosynthesis, in the absence of which NAM is used through the NAMPT-salvage pathway to generate NAD. Consequently, β-OHB accumulates, which signals HCAR2 to induce PGE 2 . Error bars, s.e.m. 
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The present results identify PGC1α as a pivotal mediator of renal resistance to acute stressors. By linking oxidative metabolism in the epithelium to overall organ function, the proposed pathway provides new insight into an old observation, namely the exquisite sensitivity of the kidney to ischaemia and other insults. More fundamentally, the results implicate NAD biosynthesis as a coordinately regulated target of PGC1α, a mechanism that may contribute to the PGC1α-dependent stress resistance previously observed across several metabolically active organs [7] [8] [9] [10] [11] . NAD has long been recognized for its central role in energy metabolism, with recent work demonstrating that NAD is rate-limiting for mitochondrial function 16 . NAD augmentation appears to restore youthful mitochondrial function and reverse age-related declines in health 17 . In contrast, NAD depletion has been described as a feature of diabetes 18 . Since diabetes and ageing are two of the most prevalent predispositions for AKI, the present results motivate interest in whether local NAD concentration may provide a set point for resistance to acute renal stressors. NAD may also be important for the gradual decline of kidney function with normal ageing.
That an even larger set of known AKI risk factors-including diabetes, but also chronic kidney disease (Extended Data Fig. 8g, h) , sepsis, and warm ischaemia-is associated with reduction of PGC1α 7 further attests to the potential relevance of the results to human disease. Experiments targeting mitochondrial biogenesis through a drug-screening approach offer additional promise for this avenue in AKI 19 . Since AKI has been associated with death in critically ill patients 1 , that excess renal PGC1α improves survival after AKI highlights the importance of the kidney to overall health. Downstream of PGC1α, NAM may not only be an effective preventative agent, but also a potential therapy for established AKI, a set of diseases for which no drug has yet been identified.
PGC1α in skeletal muscle has been shown to exert extracellular effects, whether through the myokine irisin, metabolites such as kynurenine, or the angiogenic factor VEGF 8, 9, 20 . By comparison, the present results show that renal tubular PGC1α communicates with neighbouring cells at least through PGE 2 . Therapeutic manipulation of renal β-OHB may constitute one means of increasing PGE 2 . PGE 2 is a well-recognized vasodilator in the kidney, but may also be exerting cytoprotective effects in AKI (reviewed in ref. 21 ), actions that have been demonstrated in multiple animal models and even humans 22-24 .
We observed enhanced renal function, vascular relaxation, and increased perfusion at baseline as a result of excess PGC1α in the epithelial compartment of the kidney in the iNephPGC1α model (Extended Data Fig. 9a-j) , physiological features that would be consistent with functional responses of the local vasculature to the excess renal PGE 2 present in this model. However, we also asked whether VEGF was regulated by renal PGC1α as such features could also arise from increased vascularization (Extended Data Fig. 9k-m) . PGC1α −/− mice showed no decrement in renal VEGF and iNephPGC1α mice displayed only modest induction versus their respective controls. This strongly contrasts with VEGF induction by skeletal muscle PGC1α 8 , suggesting the presence of cell-specific modulators of PGC1α function such as ERRα, which is notably more abundant in skeletal muscle than kidney (http://www.biogps.org).
Our results suggest several avenues for future investigation. First, the coordinated regulation of NAD biosynthesis by PGC1α may occur in other cells and organs, particularly under stress conditions. Of the major biosynthetic routes to NAD-de novo from amino acids, the Preiss-Handler pathway from niacin, and salvage from NAM via NAMPT-the action of PGC1α on each will require careful dissection as this may vary depending on cell type and condition. The transcription factor(s) with which PGC1α interacts to induce the de novo pathway are of substantial interest. Since ischaemia did not reduce renal NAMPT (Extended Data Fig. 10 ), the salvage pathway may be a viable therapeutic route. Second, the rapid reduction of NAD during AKI may also relate to its already short half-life 25 as well as the action of NAD-consuming enzymes such as PARPs, nucleotidases, and sirtuins, all of which have been implicated in this condition [26] [27] [28] . Third, NAD's emerging role as a guardian against age-related decline in health and mitochondrial function 17 suggests that therapeutic manipulation of NAM and NAD may have implications beyond AKI. For example, NAMPT agonism protects against experimental neuronal injury 29 , and inhibition of urinary NAM disposal (by blocking N-methylation) prevents experimental obesity 30 . Finally, the link from mitochondrial metabolism to renoprotective prostaglandins unites two major avenues of mechanistic investigation in AKI, but other mediators and downstream effectors for renal PGC1α may also exist.
In summary, the present work applies complementary discovery approaches to identify a new pathway by which parenchymal PGC1α affects NAD to protect against renal injury. The results may also have Error bars, s.e.m.; *P < 0.05, **P < 0.01, ****P < 0.0001.
Letter reSeArCH mechanistic, diagnostic, and therapeutic implications for ischaemia in the heart, brain and other metabolically active organs.
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Mouse studies. All studies with mice were reviewed and approved by the Institutional Animal Use and Care Committee of Beth Israel Deaconess Medical Center (BIDMC). Pgc1α −/− (stock no. 008597), Pax8-rtTA (no. 007176) and TRE-PGC1α (no. 012387) mice were all obtained from Jackson Laboratories and bred at BIDMC. The parental strains were generated on a mixed C57 background with further backcrossing into C57BL/6J as described by the manufacturer, except for the TRE-PGC1α mouse, which was generated on and is maintained on FVB. Primers for genotyping have been described elsewhere 31, 32 . All experiments were performed with genetically appropriate littermate controls.
Ischaemia-reperfusion injury (IRI) was performed on 8-12-week-old males through two small paramedial dorsal incisions by applying a microvascular clamp to each renal pedicle for 20 min. Mice were anaesthetized with isoflurane for the duration of surgery and warmed to 37 °C using a servo-controlled heating pad. Incisions were closed in two layers and mice were revived with 1 ml warm saline injected intraperitoneally.
All chemicals were purchased from Sigma-Aldrich unless otherwise noted. NAM was given by intraperitoneal injection of 400 mg −1 kg −1 day −1 for 4 days in saline, with the final dose an hour before IRI surgery. In rescue experiments, the same dose was administered once 18 h after reperfusion. Indomethacin was given by intraperitoneal injection of 10 mg kg −1 in 0.1 M sodium carbonate/saline an hour before IRI. The HCAR2 inhibitor, mepenzolate bromide, was given by intraperitoneal injection of 10 mg kg −1 in saline an hour before IRI [33] [34] [35] . LPS (E.coli serotype O111:B4) was given by intraperitoneal injection of 25 mg kg −1 in saline. Cisplatin was given by intraperitoneal injection of 25 mg kg −1 as previously described 36 . Unless otherwise stated, blood and kidneys were collected 24 h after the AKI model. The experiments were not randomized. Mass spectrometry measurements. All measurements were performed in a blinded fashion by an independent facility. Creatinine was analysed by LC/MS-MS at the University of Alabama Birmingham O'Brien Core Center for Acute Kidney Injury Research (NIH P30-DK079337). This method adds the accuracy of MS to the LC method of creatinine measurement endorsed by a renal investigative consortium (diacomp.org). The coefficient of variation was 6% indicating high assay precision.
For metabolomics measurements, snap frozen kidneys were cut to equal weights (20 mg per specimen) and mechanically homogenized into four volumes of icecold water. Metabolites were assayed as previously described 37 . In brief, amino acids, amines, acylcarnitines, nucleotides, and other cationic polar metabolites were measured in 10 μl of kidney homogenate using hydrophilic interaction liquid chromatography coupled with non-targeted, positive ion mode MS analysis on an Exactive Plus Orbitrap MS (Thermo Scientific). Polar and non-polar lipids were measured in 10 μl of kidney homogenate using C8 chromatography and nontargeted, positive ion mode MS analysis on a Q Exactive MS (Thermo Scientific). Identification of known metabolites was achieved by matching retention times and mass-to-charge ratio (m/z) to synthetic mixtures of reference compounds and characterized pooled plasma reference samples. Results were analysed in MetaboAnalyst (http://www.metaboanalyst.ca).
LC-MS assays were developed for multiplex quantification of NAM, NAD, and β-OHB from cellular experiments. NAD measurements reflect total NAD + plus NADH. In brief, conditioned medium was extracted with methanol (80% methanol final concentration) spiked with isotopic standards for NAM and β-OHB (CDN Isotopes, Inc.). Precipitated proteins were removed by centrifugation, and supernatants were analysed directly. For analysis of cell lysates, cells were washed with ice-cold PBS, scraped and lysed on dry ice into methanol containing isotopic standards. After extraction, cell and media supernatants were analysed by LC-MS/MS using reverse-phase chromatography (NAM and NAD/NADH) or hydrophilic interaction chromatography (β-OHB) coupled to tandem mass spectrometry using an API 5000 triple quadruple mass spectrometer. Analytes were quantified by multiple reaction monitoring using the following m/z transitions: β-OHB 103.1 > 59, β-OHB IS 105.1 > 60, NAM 123.3 > 80.2, NAM IS 127.3 > 84.2, NAD/NADH 664.2 > 542.0. Eluting peaks were quantified by area under the curve (AUC).
Raw AUC values were divided by the mean value of the control group for each experiment, thus the results are presented as relative concentrations to the control group. All assays were performed in triplicate and replicate measurements demonstrated a CV < 5%. RNA-seq sequencing and identification of differentially expressed transcripts. Poly(A)-enriched RNA was isolated from whole kidneys and checked for quality by denaturing agarose gel as well as an Agilent Bioanalyzer. Sequencing libraries were generated from the double-stranded cDNA using the Illumina TruSeq kit according to the manufacturer's protocol. Library quality control was checked using the Agilent DNA High Sensitivity Chip and qRT-PCR. High quality libraries were sequenced on an Illumina HiSeq 2000. To achieve comprehensive coverage for each sample, we generated ~25-30 million single-end reads. Raw results were passed through quality controls steps and alig ned to the mouse genome. Gene expression measurement was performed from aligned reads by counting the unique reads. The read count based gene expression data was normalized on the basis of library complexity and gene variation. The normalized count data was compared among groups using a negative binomial model to identify differentially expressed genes. The differentially expressed genes were identified on the basis of raw P value and fold change. Genes were considered significantly differentially expressed if the multiple test corrected P value was <0.05 and absolute fold change >2. Functional enrichment analysis. Ingenuity Pathway Analysis (IPA 8.0, Qiagen) was used to identify the functions that are significantly affected by significantly differentially expressed genes from different comparisons. The knowledge base of this software consists of functions, pathways, and network models derived by systematically exploring the peer reviewed scientific literature. A detailed description of IPA analysis is available at the Ingenuity Systems' website (http://www. ingenuity.com). A P value is calculated for each function according to the fit of the user's data to the IPA database using one-tailed Fisher exact test. The functions with multiple-test-corrected P values <0.01 were considered significantly affected. Western analysis. Kidney lysate preparation, gel electrophoresis, transfer, immuno blotting, detection, and image acquisition were performed as previously described 31 . Antibodies against PGC1α (Cayman Chemical), cytochrome c oxidase subunit IV (Cell Signaling Technology), and Transcription Factor A Mitochondrial, TFAM (Abcam) were used as previously described 31, 38 . Quantitative PCR. Total RNA extraction and cDNA synthesis were performed as previously described 31 . PCR reactions were performed in duplicate using the ABI 7500 Fast Real-Time PCR and TaqMan gene expression assays (Applied Biosystems). The following TaqMan gene probes were used: Ppargc1a, Ndufs1, Cycs, Atp5o, Nrf1, Tfam, Vegfa, Nos1, Nos3 and Hcar2. Of the four known Ppargc1a transcripts (1-4), Ppargc1a1 (Taqman Mm00447183_m1) was studied in all gene expression analyses 39 . Mouse Ido2, Afmid, Kynu, Kmo, Haao, Qprt, Naprt and Nmnat1 for SYBR Green PCR have been described elsewhere 40, 41 . Mouse Nampt SYBR primers were designed using PrimerQuest Tool (Integrated DNA Technologies). Relative expression levels were determined using the comparative threshold method. Mitochondrial DNA copy number analysis. Total DNA was extracted from mouse kidneys using the DNeasy Blood and Tissue Kit (Qiagen) with on-column RNase digestion per manufacturer's instructions. Gene expression of mitochondrialencoded NADH dehydrogenase 1 (mt-Nd1) relative to nuclear 18S rRNA was used to determine mitochondrial DNA copy number as previously described 42 . Histopathology. Formalin-fixed, paraffin-embedded blocks were sectioned and stained with H & E, PAS, and Masson trichrome. Ten random high-power fields in the cortex and ten random high-power fields in the outer stripe of the outer medulla were viewed and graded for tubular necrosis-defined as the loss of the proximal tubular brush border, blebbing of apical membranes, tubular necrosis/ apoptosis and epithelial cell detachment from the basement membrane or intraluminal aggregation of necrotic debris. Each high-power field was separately scored on a scale (0, no necrosis; 1, rare single necrotic cells; 2, frequent single necrotic cells; 3, groups of necrotic cells; and 4, confluent tubular necrosis) and the average score was compiled for each specimen and then used for between-group comparisons. All scoring was performed by a single operator blinded to genotype and experimental model (IES). In situ COX enzyme chemistry. Enzyme histochemistry to detect cytochrome c oxidase (COX) activity was performed on 6-μm snap-frozen sagittal sections as previously described 31 . Functional electron microscopy used in the cisplatin kidney injury model was described earlier 36 . Electron microscopy. The complete method is previously described 31 . In brief, kidneys were fixed with 1.25% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and cut into 1-μm sections in both sagittal and transverse planes for image analysis. After drying the sections, slides were stained at 65 °C for 20 min in 0.1% Toluidine blue in 1% sodium borate, cooled to room temperature, washed in distilled water, cleaned in xylene, and mounted in Permount sections for light microscopy. Subsequent ultrathin sections (0.5 μm) were examined by transmission electron microscopy (JEOL 1011, JEOL Corp.) with Orca-HR Digital Camera (Hamamatsu Corp.), and Advanced Microscopy Technique Corporation image capture system. Oil-Red-O staining. Oil-Red-O solution was prepared by dissolving 0.5 g OilRed-O (Poly Scientific) in 100 ml isopropanol. Frozen sections were cut to 5 μm and natively stained in Oil-Red-O solution for 20 min at room temperature, then rinsed in running tap water for 2 min. Haematoxylin counter-staining was performed without differentiation in HCl-ethanol and sections were rinsed with water, then mounted with VectaMount AQ Aqueous Mounting medium (Vector Labs).
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Human biopsy series. All studies were approved by the Institutional Review Board at BIDMC. Control specimens came from normal tissue sections of nephrectomies. CKD diagnoses included focal segmental glomerulosclerosis, chronic allograft nephropathy, chronic interstitial nephritis, and chronic IgA nephropathy. AKI diagnoses included acute ischaemic injury, post-transplant delayed graft function attributable to ischaemia-reperfusion injury, and acute interstitial nephritis. PGC1α antibody (Abcam ab54481) was used at a dilution of 1:100 and developed with horseradish peroxidase (ImmPRESS polymer staining kit, Vector Labs). The peptide immunogen SKYDSLDFDSLLKEAQRSLRR (synthesized by the Biopolymers Lab, Koch Institute at MIT) was pre-incubated in 100-fold excess of the PGC1α antibody to confirm antibody specificity in human IHC studies. Ten randomly selected high-powered fields were viewed per specimen, with each field scored on a 4-point scale (1, weakest; 4, strongest) based on the intensity of staining, specifically in non-necrotic areas and unscarred areas and avoiding obvious collecting ducts. The average score of each specimen was then used for betweengroup comparisons. All scoring was performed by a single operator blinded to the underlying diagnosis (IES). Micro-ultrasound. The full method is previously described 31 . In brief, mice were lightly anaesthetized, secured to a heat-controlled stage, and continuously monitored for respiration, ECG, and core temperature. A high-frequency, highresolution digital imaging platform with linear array technology and equipped with a high-frequency linear array probe MS550D (22-55 MHz) was used throughout the study (Vevo 2100 Visual Sonics). The flow volume was modelled as a circular cylinder of length equal to the average velocity time integral and diameter measured empirically (n = 3 cardiac cycles), then multiplied by the heart rate (b.p.m.), then converted from mm 3 min −1 to ml min −1
. All measurements and analyses were performed by a single blinded operator (EVK). Cellular studies. Mouse inner medullary collecting duct (IMCD3) cells were obtained from ATCC. Please refer to their website for validation and mycoplasma testing (http://www.atcc.org/Products/All/CRL-2123.aspx). Cells were transfected with siRNA targeting mouse PGC1α, HCAR2 or a negative control siRNA (Qiagen) for 24 h. Niacin, mepenzolate bromide, β-hydroxybutyrate, the NAMPT inhibitor FK866 (ref. 43) , and NAM were diluted to the indicated concentrations in serum-free cell culture medium. Prostaglandin E2 (PGE 2 ) was measured in the conditioned media 24-72 h after treatment. Cystatin C. Cystatin C in mouse serum (1:200 dilution) was measured by ELISA (R&D Systems). FITC-inulin clearance. The full method is described elsewhere 44 . In brief, male C57BL/6J mice (Jackson Laboratories) were given a single bolus injection of 5%-FITC-inulin (3.74 μl per g body weight). Clearance kinetics of FITC-inulin post-injection was measured by serial blood collection at specified time points from 3 through 70 min post-injection. Blood samples were centrifuged and resulting plasma was buffered to pH 7.4 with 500 mM HEPES. Fluorescence in the buffered plasma samples was determined with 485 nm excitation, 538 nm emission. Glomerular filtration rate (GFR) was calculated from the two-phase exponential decay model outlined previously. Tissue PGE 2 , β-OHB, and NAD measurements. PGE 2 was measured in mouse kidney tissue by ELISA (Cayman Chemical). β-OHB (Cayman Chemical) and total NAD (BioVision) were measured in mouse kidney tissue by colorimetric assays. These assays were performed on kidneys used for metabolomics and lipidomics in order to compare coordinated changes in metabolism and downstream signalling. NAD measurements reflect total NAD + plus NADH. Statistical analysis. Comparisons between continuous characteristics of subject groups were analysed with Mann-Whitney U-tests or Student's t-test. Survival was analysed by log-rank test. For comparisons among more than two groups, ANOVA with Bonferroni's correction was used where indicated. Associations between micro-ultrasound measurements and other functional parameters were analysed with Spearman's rank correlation coefficients. Sample size determination was guided by power calculations and prior experience. The following sample calculation was used to guide creatinine studies in mice: serum creatinine of 1.6 (±0.3 s.d.) mg dl −1 versus 1.0 (±0.2 s.d.) requires n = 5 mice per condition to achieve an α-error <5% and power 96%. Mice were randomized to experimental intervention versus control. Two-tailed P values < 0.05 were considered significant. Results are presented as mean ± s.e.m. and were prepared in GraphPad Prism.
